|
Jun 10
|
1 Unprofitable Stock for Long-Term Investors and 2 to Ignore
|
|
May 12
|
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
|
|
Mar 26
|
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
|
|
Mar 25
|
Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?
|
|
Mar 12
|
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
|
|
Mar 11
|
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
|
|
Feb 21
|
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
|
|
Feb 21
|
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Feb 21
|
Q4 2024 Repligen Corp Earnings Call
|
|
Feb 20
|
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
|
|
Feb 20
|
February 2025's US Stocks That May Be Trading Below Fair Value
|
|
Feb 20
|
Repligen (RGEN) Beats Q4 Earnings Estimates
|
|
Feb 20
|
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
|
|
Feb 20
|
Repligen: Q4 Earnings Snapshot
|
|
Feb 20
|
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 19
|
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
|
|
Feb 18
|
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price
|
|
Jan 14
|
HRMY or RGEN: Which Is the Better Value Stock Right Now?
|